Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
Incyte Corp. said Monday it reached a deal with the Food and Drug Administration on a design for a late-stage study of a potential treatment for a blood cancer.
The company is developing INCB18424 as a treatment for polycythemia vera, a blood disorder in which the bone marrow overproduces red blood cells and makes the blood too thick.
The study is expected to enroll 300 patients, with enrollment beginning in the U.S. in October.
Shares of Incyte fell 9 cents to $13.97 in afternoon trading.